Follow-up of patients with thyroglobulin-antibodies: Rising Tg-Ab trend is a risk factor for recurrence of differentiated thyroid cancer

References

• Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306. doi: 10.1056/NEJM199801293380506.
   PubMed Web of Science ®Google Scholar
• Ringel M, Nabhan F. Approach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies. J Clin Endocrinol Metab. 2013;98:3104–3110. doi: 10.1210/jc.2013-1412.
   PubMed Web of Science ®Google Scholar
• Pacini F, Mariotti S, Formica N, et al. Thyroid autoantibodies in thyroid cancer: Incidence and relationship with tumour outcome. Acta Endocrinol. 1988;119:373–380.
   PubMedGoogle Scholar
• Spencer CA, Bergoglio LM, Kazarosyan M, et al. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2005;90:5566–5575. doi: 10.1210/jc.2005-0671.
   PubMed Web of Science ®Google Scholar
• Giovanella L, Clark P, Chiovato L, et al. Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: A clinical position paper. Eur J Endocrinol. 2014;171:R33–R46. doi: 10.1530/EJE-14-0148.
   PubMed Web of Science ®Google Scholar
• Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: Prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:1121–1127. doi: 10.1210/jcem.83.4.4683.
   Google Scholar
• Chung J, Park YJ, Kim TY, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf). 2002;57:215–221.
   PubMed Web of Science ®Google Scholar
• Görges R, Maniecki M, Jentzen W, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol. 2005;153:49–55. doi: 10.1530/eje.1.01940.
   PubMed Web of Science ®Google Scholar
• Seo J, Lee S, Ahn B, et al. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: Special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol (Oxf). 2010;72:558–563. doi: 10.1111/j.1365-2265.2009.03693.x.
   PubMed Web of Science ®Google Scholar
• Hsieh C, Wang P. Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease activity in thyroglobulin-negative patients with papillary thyroid carcinoma. Thyroid. 2014;24:488–493. doi: 10.1089/thy.2012.0611.
   PubMed Web of Science ®Google Scholar
• Smooke Praw S, Ro K, Levin O, et al. Thyroglobulin antibody levels do not predict disease status in papillary thyroid cancer. Clin Endocrinol (Oxf). 2014;81:271–275. doi: 10.1111/cen.12421.
   PubMed Web of Science ®Google Scholar
• Yoon J, Kim W, Kim T, et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2008;93:4683–4689. doi: 10.1210/jc.2008-0962.
   PubMed Web of Science ®Google Scholar
• Haugen B, Alexander E, Bible K, et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. doi: 10.1089/thy.2015.0020.
   PubMed Web of Science ®Google Scholar
• Verburg F, Luster M, Cupini C, et al. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: A clinical position statement. Thyroid. 2013;23:1211–1225. doi: 10.1089/thy.2012.0606.
   PubMed Web of Science ®Google Scholar
• Chiovato L, Latrofa F, Braverman L, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med. 2003;139:346–351.
   PubMed Web of Science ®Google Scholar
• Cooper D, Doherty G, Haugen B, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214. doi: 10.1089/thy.2009.0110.
   PubMed Web of Science ®Google Scholar
• Pacini F, Castagna MG, Brilli L, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5): v214–9. doi: 10.1093/annonc/mdq190.
   PubMed Web of Science ®Google Scholar
• Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803. doi: 10.1530/eje.1.02158.
   PubMed Web of Science ®Google Scholar
• Pitoia F, Ward L, Wohllk N, et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2009;53:884–887.
   PubMedGoogle Scholar
• Gharib H, Papini E, Valcavi R, et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2006;12:63–102. doi: 10.4158/EP.12.1.63.
   PubMedGoogle Scholar
• Freudenberg L, Jentzen W, Stahl A, et al. Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2011; 38(Suppl1): S48–56. doi: 10.1007/s00259-011-1773-5.
   PubMed Web of Science ®Google Scholar
• Van Nostrand D, Khorjekar G, O’Neil J, et al. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET. J Nucl Med. 2012;53:359–362. doi: 10.2967/jnumed.111.096016.
   PubMed Web of Science ®Google Scholar
• Ozkan E, Soydal C, Araz M, et al. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels. Clin Nucl Med. 2012;37:755–758. doi: 10.1097/RLU.0b013e31825ae77b.
   PubMed Web of Science ®Google Scholar
• Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:3668–3673. doi: 10.1210/jc.2002-021925.
   PubMed Web of Science ®Google Scholar